Supreet Sahai, MD
Neurology · Los Angeles, CANPI 1538587159
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,346 of the $4,951 with a category attached, or 87.8%. 25 manufacturers reported payments, led by AbbVie at 27.4% of the total. 2025 is the largest year on record at $1,221, more than ten times the $121 reported in 2019.
Across 203 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$565
- Pfizer$550
- Natus Medical Incorporated$525
- Abbott$357
- Lundbeck LLC$262
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$52511%
- Food & beverage$4,34688%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,356 |
| Teva Pharmaceuticals USA, Inc. | 32 | $565 |
| Pfizer | 35 | $550 |
| Natus Medical Incorporated | 1 | $525 |
| Abbott | 4 | $357 |
| Lundbeck LLC | 15 | $262 |
| Axsome Therapeutics, Inc. | 3 | $184 |
| Biogen | 10 | $183 |
| Neurocrine Biosciences, Inc. | 1 | $173 |
| Argenx US, Inc. | 7 | $158 |
| Merz Pharmaceuticals, LLC | 3 | $123 |
| AstraZeneca | 1 | $121 |
| Eisai Inc. | 3 | $76 |
| Lilly USA, LLC | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Livanova USA, Inc. | 1 | $27 |
| Neurelis, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,951 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.